Ocaliva‘s Exit: A Turning Point in Primary Biliary Cholangitis Treatment
The landscape of primary biliary cholangitis (PBC) treatment has shifted significantly with the recent decision by Intercept to discontinue marketing Ocaliva (obeticholic acid) in the United States, following a request from the Food and Drug Governance (FDA). This move marks the end of a challenging journey for the drug and signals a new era for patients and healthcare providers managing this rare liver disease.
A History of Regulatory hurdles and Safety Concerns
Originally approved under accelerated approval in 2016, Ocaliva aimed to address a critical unmet need in PBC. Though, the path to full approval proved fraught with obstacles. The FDA ultimately rejected Intercept’s application for complete approval, citing concerns about long-term safety and efficacy.
Simultaneously, the agency issued a safety communication highlighting a risk of serious liver injury in patients without cirrhosis, prompting increased scrutiny. These concerns were echoed internationally, leading to the revocation of Ocaliva’s conditional marketing authorization in Europe.
Setbacks Beyond PBC
Intercept’s struggles extended beyond its initial PBC indication. The FDA twice declined to approve Ocaliva as a treatment for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH).
Following these setbacks,Intercept underwent a restructuring and was subsequently acquired by Alfasigma,a privately held pharmaceutical company. This acquisition occurred in late 2023, reflecting the significant challenges the company faced.
The Rise of New Treatment Options
Fortunately, the treatment options for PBC have expanded in recent years, providing patients and physicians with alternatives.In 2024,the FDA granted accelerated approval to two novel therapies:
* Iqirvo (lansoprazole plus mirabegron): Developed by Ipsen,this combination medication offers a different mechanism of action for managing PBC.
* livdelzi (seladelpar): From Gilead Sciences, Livdelzi also provides an option approach to treating the disease.
These newer drugs are positioned as second-line treatments, comparable to Ocaliva in terms of their intended use. Importantly,neither Iqirvo nor Livdelzi carries the “black box” warning associated with Ocaliva,indicating a perhaps more favorable safety profile.
Why Ocaliva is Leaving the Market
With safer alternatives now available, the FDA determined that maintaining ocaliva’s accelerated approval status was no longer warranted. The agency’s decision reflects a reassessment of the drug’s benefit-risk profile in light of the evolving treatment landscape.
While Intercept maintains its belief in Ocaliva’s clinical value, the company has chosen to respect the FDA’s request and discontinue its marketing. “While our view of Ocaliva’s benefit-risk profile differs from FDA’s, we respect its request and have made this difficult decision to provide clear guidance for patients and prescribers,” stated Vivek Devaraj, U.S. president at Intercept.
What this Means for You
If you are currently taking Ocaliva, it’s crucial to discuss your treatment plan with your healthcare provider. They will work with you to transition to an appropriate alternative therapy, ensuring continuity of care and optimal disease management.
The availability of Iqirvo and Livdelzi represents a positive advancement for the PBC community, offering new hope and improved treatment options. As research continues, we can anticipate further advancements in the understanding and management of this complex liver disease.